2024
DOI: 10.46234/ccdcw2024.047
|View full text |Cite
|
Sign up to set email alerts
|

Epidemiological Characteristics of Human Parainfluenza Viruses Infections — China, 2019–2023

Yixuan Gao,
Yingwei Ma,
Daxing Feng
et al.

Abstract: Introduction A retrospective study based on sentinel surveillance was conducted in 10 provincial-level administrative divisions (PLADs) in China to enhance the understanding of the epidemiological characteristics of human parainfluenza viruses (HPIVs). Methods From January 2019 to June 2023, respiratory specimens were collected from individuals with acute respiratory infections (ARIs) and screened for four HPIVs serotypes and other common respiratory viruses using multi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 11 publications
0
1
0
Order By: Relevance
“…Yet, an obvious resurgence was absent in the first quarter of 2020 and the fourth quarters of 2019 and 2022, suggesting a potential peak delayed to 2023. The effects of strict NPIs against COVID-19 may have contributed to alterations in the seasonal patterns of viral infections in other Chinese populations as well 37 , 38 . Typical seasonal patterns were also observed in the number of S. aureus isolates resistant to penicillin, erythromycin, and clindamycin in 2018, 2019, and 2021.…”
Section: Discussionmentioning
confidence: 99%
“…Yet, an obvious resurgence was absent in the first quarter of 2020 and the fourth quarters of 2019 and 2022, suggesting a potential peak delayed to 2023. The effects of strict NPIs against COVID-19 may have contributed to alterations in the seasonal patterns of viral infections in other Chinese populations as well 37 , 38 . Typical seasonal patterns were also observed in the number of S. aureus isolates resistant to penicillin, erythromycin, and clindamycin in 2018, 2019, and 2021.…”
Section: Discussionmentioning
confidence: 99%